Harvard Bioscience Financials - Benzinga

Harvard Bioscience Inc

HBIONASDAQ

Trade with Public

Trade with Public

$7.92

-0.04-0.5%

가까이에: Sep 30, 5:00 PM EST

$7.92

N/A

시간외: 4:26 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 주식 보고서

Harvard Bioscience Financials

Harvard Bioscience (HBIO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est.

Harvard Bioscience (NASDAQ:HBIO) sees FY2026 sales of $89.147 million-$90.877 million vs $88.600 million analyst estimate. Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth.

Benzinga Newsdesk

PRO
Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est

Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $21.000 million-$22.600 million vs $21.850 million analyst estimate.

Benzinga Newsdesk

PRO
Harvard Bioscience Q2 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $22.727M Beat $21.450M Estimate

Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 33.33 percent. This is a 40 percent decrease over losses of $(0.10) per share from

Benzinga Newsdesk

PRO
Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est

Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million analyst estimate.

Benzinga Newsdesk

PRO
Harvard Bioscience Q1 Adj. EPS $(0.33) Beats $(0.62) Estimate, Sales $20.755M Miss $21.200M Estimate

Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.62) by 46.77 percent. This is a 230 percent decrease over losses of $(0.10) per share from

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved